The company has grown its revenue from R$3.9B in 2021 to R$8.3B by 2025 through mergers and acquisitions — This indicates strong consolidation efforts, suggesting potential for further growth.
It trades at approximately 15x P/E and ~1.9x book value — Suggests the stock might be undervalued given its earnings power.
Future expansion in smaller markets could drive additional revenue growth
PLATAFORMA DE RESEARCH · BRASIL HORIZONTEOPINIÑO DO IANALISTA: Fleury S.A.FLRY3Saúde — Medicina Diagnóstica — B3 · Novo MercadoResumo Executivo · 5 de agosto de 2026 Preço R$ 17,49 · Market Cap R$ 9,6 Bi · P/L 15,1x · P/VPA ~1,9x · ROE ~12% · Div.
